跳到正文
MarketHOT
English
摘要
SEC · EDGAR 财务披露·· 13 小时前AI 评分32

CV Sciences 与前法律顾问的仲裁案已和解

CV Sciences, Inc. (0001510964) (Filer)

AI 导读

CV Sciences 与前法律顾问之间的仲裁案已达成和解,公司收到 50 万美元,双方相互解除对彼此的所有索赔。该事项载于公司提交的 Form 8-K。

正文

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 23, 2026

CV SCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware

000-54677

80-0944970

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

9530 Padgett Street, Suite 107

San Diego, California

92126

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (866) 290-2157

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange on which registered

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01 Other Events

As previously reported by the Company on February 12, 2025, the Company initiated an arbitration with JAMS against its former legal counsel. This case has been settled. Under the terms of the settlement, the Company has received $500,000, and the Company and its former legal counsel have mutually released all claims against each other.

1


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CV SCIENCES, INC.

Date: October 26, 2026

By:

/s/ Joseph Dowling

Joseph Dowling

Chief Executive Officer

2


来源:SEC EDGAR · 本站存档